5-MeO-MiPT
5-MeO-MiPT is a synthetic psychedelic and entactogenic substance of the tryptamine class. Its synthesis and human psychopharmacology were first published by Shulgin, Repke, and colleagues in 198512, with further documentation in Shulgin's 1997 book TiHKAL3. The substance is characterized by its notably stimulating and body-oriented effects, including pronounced tactile and sexual enhancement3, while generally producing fewer visual distortions than typical psychedelics.1 It is almost exclusively obtained as a research chemical through online vendors.
Contents
Dosage & Duration
Dosage
Users report steep dosage curve. Start lower than expected.
Duration
Subjective Effects
Effects vary widely by individual, dose, and context.
Physical
The physical effects of 5-MeO-MiPT can be broken down into three components all of which progressively intensify proportional to dosage.
Cognitive
The head space of 5-MeO-MiPT is described by many as one which is both insightful and moderately relaxing, but at some points quite stimulating.
Visual
Geometry
The visual geometry that is present throughout this trip can be described as more similar in appearance to that of psilocin, 4-AcO-DMT, or ayahuasca than that of LSD or 2C-B. They can be comprehensively described as structured in their organization, organic in geometric style, intricate in complexity, large in size, fast and smooth in motion, colourful in scheme, glossy in colour, equal in blurred and sharp edges, and equal in rounded and angular corners. At higher dosages, they are significantly more likely to result in states of level 7B visual geometry over level 7A. In terms of their manifestation, they are progressive in nature and continuously self-complexify in settings with little to no visual input and disturbances.
Hallucinatory States
5-MeO-MiPT produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics.
Auditory
The auditory effects of 5-MeO-MiPT are common in their occurrence and exhibit a full range of effects.
Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
5-MeO-MiPT acts primarily as a serotonin receptor agonist, with its psychedelic effects thought to result mainly from partial agonism at the 5-HT2A receptor.4 The compound shows its strongest binding affinity at the 5-HT1A receptor5 and also interacts with 5-HT2C and 5-HT2B receptors at lower potencies. One study reported modest affinity for the serotonin transporter, suggesting possible serotonin-norepinephrine reuptake inhibition,6 while another found no significant activity at the monoamine transporters at concentrations up to 10 μM;7 the compound is also inactive as a monoamine releasing agent.5 Inhibition of monoamine oxidase has been speculated as an additional mechanism but remains undemonstrated.
Pharmacokinetics
5-MeO-MiPT undergoes extensive phase I hepatic metabolism mediated by cytochrome P450 enzymes. The major metabolic pathways include O-demethylation, N-demethylation, hydroxylation, and N-oxide formation.89 Multiple metabolites have been detected in human urine9 within two hours of exposure, and blood concentrations are measurable within one hour, suggesting relatively rapid metabolism and elimination. Renal excretion is thought to be a major route of elimination.
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Serotonergic psychedelics
Harm Potential
Addiction & Dependence
Psychological
Extremely Low5-MeO-MiPT is not typically associated with habit formation, and interest in taking it may lessen after repeated experiences. Its use is usually self-limiting, though some people may still use it more often than feels comfortable.
Physical
Extremely Low5-MeO-MiPT is not physically addictive. There is no evidence of physical dependence or withdrawal symptoms associated with its use.10
Toxicity
Doses approximately 10 times above normal recreational ranges have been shown to induce cell toxicity in brain tissue in animal studies; low-dose use did not cause any serious histopathological effects in this organ.2
High doses well above normal ranges have been shown to produce cell toxicity in liver tissue in animal studies; low-dose use did not cause serious histopathological effects.2
High doses well above normal ranges have been shown to produce cell toxicity in kidney tissue in animal studies; low-dose use did not cause serious histopathological effects.2
Vasoconstriction, increased heart rate, and elevated blood pressure are commonly reported during acute intoxication; cardiac problems including tachycardia and chest pain have been reported particularly after doses exceeding 10 mg.
Psychosis Risk
Temporary psychosis, confusion, disorientation, and agitation have been documented in several clinical case reports, typically associated with high doses or combination with other substances.912 One case involved a 32-year-old male found disoriented and aggressive after confirmed use. People with schizophrenia in their family history or a history of early-onset mental illness should be extremely cautious, because psychedelics may bring underlying psychological vulnerabilities to the surface.
Seizure Risk
People with seizure or convulsive disorders could face increased health risks from psychedelic use, although the literature does not provide specific seizure risk data for 5-MeO-MiPT.
History & Culture
5-MeO-MiPT, commonly known as "Moxy," was first synthesized and characterized in 1985 when David Repke, Donald Grotjahn, and Alexander Shulgin published its synthesis and pharmacological profile in the Journal of Medicinal Chemistry.13 This…
Trip Reports
Loading related reports
Preparing section content
Still loading. Refresh if this section does not appear.
Legality
International
1961 Single Convention: 5-MeO-MiPT is not individually scheduled.
1971 Convention on Psychotropic Substances: 5-MeO-MiPT is not individually scheduled.
1988 Convention: 5-MeO-MiPT is not listed in precursor Tables I or II.
By Country
References
Source Pages
Citations
- (July 1985). Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents. Journal of Medicinal Chemistry, 28(7), 892–896. https://doi.org/10.1021/jm00145a007123
- (January 2021). New Psychoactive Substance 5-MeO-MiPT In vivo Acute Toxicity and Hystotoxicological Study. Balkan Medical Journal, 38(1), 34–42. https://doi.org/10.4274/balkanmedj.galenos.2020.2019.11.6812345
- Aragón M. (2024-01-09). Meet Moxy: The Novel Psychedelic the DEA Tried To Ban. DoubleBlind Mag. https://doubleblindmag.com/what-is-moxy/12345678
- (August 2016). Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. European Neuropsychopharmacology, 26(8), 1327–1337. https://doi.org/10.1016/j.euroneuro.2016.05.0011
- (August 2024). Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties. Molecular Psychiatry, 29(8), 2346–2358. https://doi.org/10.1038/s41380-024-02506-812
- (March 2007). The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. European Journal of Pharmacology, 559(2–3), 132–137. https://doi.org/10.1016/j.ejphar.2006.11.0751
- (n.d.). Reference (doi:10.1007/s00213-014-3557-7). https://doi.org/10.1007/s00213-014-3557-712
- (n.d.). The predicted human percent unbound to blood plasma Protein|proteins was 45.5%, compared to 31.6% in mice. The predicted volume of distribution. https://doi.org/10.1016/j.jpba.2024.1159871
- (n.d.). At lower doses of 0.27 mg/kg, concentrations of the parent compound remained below the limit of quantification in all samples. In one human c. https://doi.org/10.1002/dta.2245123
- Nichols DE. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355. https://doi.org/10.1124/pr.115.0114781
- (November 2016). Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats. Neurotoxicity Research, 30(4), 606–619. https://doi.org/10.1007/s12640-016-9654-01
- (March 2024). Pharmaco-toxicological effects of the novel tryptamine hallucinogen 5-MeO-MiPT on motor, sensorimotor, physiological, and cardiorespiratory parameters in mice-from a human poisoning case to the preclinical evidence. Psychopharmacology, 241(3), 489–511. https://doi.org/10.1007/s00213-024-06526-81
- (n.d.). Anlage zum Neue-psychoaktive-Stoffe-Gesetz (NpSG) – Stoffgruppe 5: Von Tryptamin abgeleitete Verbindungen. Bundesministerium der Justiz. https://www.gesetze-im-internet.de/npsg/anlage_1.html1
- (n.d.). Misuse of Drugs Act 1971 generic tryptamine control. gov.uk. https://www.gov.uk/government/publications/forensic-early-warning-system-fews-annual-report/annual-report-on-the-home-office-forensic-early-warning-system-fews-2021-to-20221
- (n.d.). 21 CFR § 1308.11(d). ecfr.gov. https://www.ecfr.gov/current/title-21/chapter-II/part-1308/section-1308.111
Further Reading
- Reviewed & approved
Reviewed, edited, and approved by subject-matter expert Lyrea.
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 5-MeO-MiPT article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
